Clinical utility gene card for: Hyperlipoproteinemia, TYPE II

European Journal of Human Genetics

Volumn 22, Issue 7, 2014, Pages 953-

  Kassner, Ursula ^a   Wühle Demuth, Marion ^a   Missala, Isabelle ^a   Humphries, Steve E ^b   Steinhagen Thiessen, Elisabeth ^a   Demuth, Ilja ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

APOB GENE; ARTICLE; DIFFERENTIAL DIAGNOSIS; EXON; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENE MUTATION; GENE REARRANGEMENT; GENETIC RISK; GENETIC SCREENING; HUMAN; LDLR GENE; LIFESTYLE MODIFICATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PCSK9 GENE; PREDICTIVE VALUE; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; FEMALE; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; MALE;

APOLIPOPROTEIN B-100; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84902304578     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.271     Document Type: Article

References (23)

1. Usifo E, Leigh SE, Whittall RA et al: Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: Update and pathological assessment. Annals of human genetics 2012; 76: 387-401
2. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ: Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proceedings of the National Academy of Sciences of the United States of America 1989; 86: 587-591. (Pubitemid 19037786
3. Nordestgaard BG, Chapman MJ, Humphries SE et al: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European heart journal 2013; doi:10.1093/eurheartj/eht273
4. Varret M, Abifadel M, Rabes JP, Boileau C: Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clinical genetics 2008; 73: 1-13. (Pubitemid 350263516
5. Abifadel M, Rabes JP, Devillers M et al: Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Human mutation 2009; 30: 520-529
6. Futema M, Plagnol V, Whittall RA et al: Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia. Journal of medical genetics 2012; 49: 644-649
7. Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM: Familial hypercholesterolemia: Epidemiology, Neolithic origins and modern geographic distribution. Critical reviews in clinical laboratory sciences 2011; 48: 1-18
8. Vuorio AF, Turtola H, Piilahti KM, Repo P, Kanninen T, Kontula K: Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arteriosclerosis, thrombosis, and vascular biology 1997; 17: 3127-3138
9. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG: Familial hypercholesterolemia in the danish general population: Prevalence, coronary artery disease, and cholesterol-lowering medication. The Journal of clinical endocrinology and metabolism 2012; 97: 3956-3964
10. Taylor A, Wang D, Patel K et al: Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clinical genetics 2010; 77: 572-580
11. Hooper AJ, Nguyen LT, Burnett JR et al: Genetic analysis of familial hypercholesterolaemia in Western Australia. Atherosclerosis 2012; 224: 430-434
12. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD: Screening and treatment for lipid disorders in children and adolescents: Systematic evidence review for the US Preventive Services Task Force. Pediatrics 2007; 120: E189-e214
13. Huijgen R, Kindt I, Fouchier SW et al: Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Human mutation 2010; 31: 752-760
14. Wierzbicki AS, Humphries SE, Minhas R: Guideline Development G: Familial hypercholesterolaemia: Summary of NICE guidance. Bmj 2008; 337: A1095
15. van Aalst-Cohen ES, Jansen AC, Tanck MW et al: Diagnosing familial hypercholesterolaemia: The relevance of genetic testing. European heart journal 2006; 27: 2240-2246. (Pubitemid 44412840
16. European Association for Cardiovascular P, RehabilitationReiner Z, Catapano AL, De Backer G et al: ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European heart journal 2011; 32: 1769-1818
17. Shafiq N, Singh M, Kaur S, Khosla P, Malhotra S: Dietary treatment for familial hypercholesterolaemia. Cochrane database of systematic reviews 2010; 1: CD001918
18. Lahera V, Goicoechea M, de Vinuesa SG et al: Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins. Current medicinal chemistry 2007; 14: 243-248. (Pubitemid 46043919
19. Cholesterol Treatment Trialists CBaigent C, Blackwell L, Emberson J et al: Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of data from 170000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681
20. Thompsen J, Thompson PD: A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006; 189: 31-38. (Pubitemid 44444914
21. Starr B, Hadfield SG, Hutten BA et al: Development of sensitive and specific age-And gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clinical chemistry and laboratory medicine: CCLM/FESCC 2008; 46: 791-803. (Pubitemid 351821631
22. Lee P, Hegele RA: Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert opinion on investigational drugs 2013; 22: 1411-1423
23. Versmissen J, Oosterveer DM, Yazdanpanah M et al: Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. Bmj 2008; 337: A2423.